Synagis (palivizumab) to prevent respiratory syncytial virus (RSV) infections in young children

Physicians can now use Synagis (palivizumab) to prevent respiratory syncytial virus (RSV) infections in young children.

It's for children under 2 who are at risk for serious RSV infection in the lungs...due to premature birth or chronic lung disease.

Synagis is a monoclonal antibody. It binds to a protein on the surface of the virus to prevent it from infecting cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote